U.S., Sept. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07155590) titled 'Subphenotype- and Complication-guided Adjunctive Fosfomycin Therapy for Staphylococcus Aureus Bacteraemia: Pooled Analysis of Two Randomised Trials' on Aug. 27.
Brief Summary: Staphylococcus aureus bacteraemia (SAB) is a major global cause of sepsis-related mortality. Randomised trials of adjunctive antibiotics, including fosfomycin, have not shown consistent benefit, possibly due to inclusion of unselected SAB populations. The FEN-AUREUS classification enables early risk stratification based on clinical subphenotypes. We aim to validate this framework in a pooled trial cohort and assess whether combining subphenotypes with IDSA-def...